A Phase 1/2 Multiple Ascending Dose Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of BMS-911543 in Subjects With Myelofibrosis
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 98
- 试验地点
- 4
- 主要终点
- Number of Participants With Adverse Events
研究概览
简要总结
The purpose of this first in human study is to determine if BMS-911543 is safe and tolerable in subjects with symptomatic intermediate-1, intermediate-2 or high risk myelofibrosis to permit clinical testing at the Maximum Tolerated Dose or at a Clinically Active Dose, and to determine if BMS-911543 will demonstrate efficacy in symptomatic myelofibrosis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and Women at least 18 years old
- •A diagnosis of symptomatic, primary or secondary Myelofibrosis (MF) [World Health Organization (WHO) 2008 criteria] with intermediate-1, intermediate-2 or high risk disease as assessed using the Dynamic International Prognostic Scoring System international prognostic scoring system
- •Last therapeutic or diagnostic treatment at least 28 days prior
- •Any toxicity from prior therapies must have resolved to Grade ≤1
- •Adequate Liver and Kidney Function
- •Serum amylase and lipase within normal institutional range
- •Platelet count ≥50,000 cell mm³
- •Absolute neutrophil count (ANC) ≥1,000 cells/mm3
- •Hemoglobin ≥8.0 g/dL
排除标准
- •Primary central nervous system tumors
- •Subjects with currently active malignancy (other than MF) or with a prior history of malignancy with the exception of: (i) adequately treated basal cell carcinoma of the skin, (ii) curatively treated in situ carcinoma of the cervix, (iii) other malignancy that has undergone potentially curative therapy with no evidence of disease recurrence ≥3 years
- •Any condition requiring chronic use of moderate/high dose steroids except inhalation or oral steroids for mild pulmonary disease
- •Splenic irradiation ≤3 months prior to treatment with study drug
- •Positive blood screen for hepatitis C antibody, hepatitis B surface antigen or Human Immunodeficiency Virus-1 (HIV-1), or HIV-2 antibodies
- •Abnormalities in serum electrolytes
- •Significant cardiovascular disease
- •Current or recent gastrointestinal disease
- •Previous history of pancreatitis and/or significant risk factors for pancreatitis as judged by the treating physician
- •Evidence of uncontrolled active infection or active graft vs. host disease
- •Inability to tolerate oral medication
研究组 & 干预措施
Phase 1 (Cohort 1): BMS-911543 (5 mg)
BMS-911543 5 mg capsule by mouth twice daily for 12 months or greater depending on response
干预措施: BMS-911543 (Drug)
Phase 1 (Cohort 2): BMS-911543 (10 mg)
BMS-911543 10 mg capsule by mouth twice daily for 12 months or greater depending on response
干预措施: BMS-911543 (Drug)
Phase 1 (Cohort 3): BMS-911543 (20 mg)
BMS-911543 20 mg capsule by mouth twice daily for 12 months or greater depending on response
干预措施: BMS-911543 (Drug)
Phase 1 (Cohort 4): BMS-911543 (40 mg)
BMS-911543 40 mg capsule by mouth twice daily for 12 months or greater depending on response
干预措施: BMS-911543 (Drug)
Phase 1 (Cohort 5): BMS-911543 (80 mg)
BMS-911543 80 mg capsule by mouth twice daily for 12 months or greater depending on response
干预措施: BMS-911543 (Drug)
Phase 1 (Cohort 6): BMS-911543 (120 mg)
BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
干预措施: BMS-911543 (Drug)
Phase 1 (Cohort 7): BMS-911543 (160 mg)
BMS-911543 160 mg capsule by mouth twice daily for 12 months or greater depending on response
干预措施: BMS-911543 (Drug)
Phase 1 (Cohort 8): BMS-911543 (200 mg)
BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
干预措施: BMS-911543 (Drug)
Phase 1 (Cohort 9): BMS-911543 (240 mg)
BMS-911543 240 mg capsule by mouth twice daily for 12 months or greater depending on response
干预措施: BMS-911543 (Drug)
Phase 1 (Cohort 10): BMS-911543 (320 mg)
BMS-911543 320 mg capsule by mouth twice daily for 12 months or greater depending on response
干预措施: BMS-911543 (Drug)
Phase 2 (Cohort 11): BMS-911543 (120 mg)
BMS-911543 120 mg capsule by mouth twice daily for 12 months or greater depending on response
干预措施: BMS-911543 (Drug)
Phase 2 (Cohort 12): BMS-911543 (200 mg)
BMS-911543 200 mg capsule by mouth twice daily for 12 months or greater depending on response
干预措施: BMS-911543 (Drug)
结局指标
主要结局
Number of Participants With Adverse Events
时间窗: From the date of participant's written consent until 30 days post discontinuation of dosing or participation in the study if the last scheduled visit occured at a later time, assessed up to 4.5 years
Safety assessments were based on a medical review of adverse event reports and the results of vital sign measurements, ECGs, physical examinations, and clinical laboratory tests and were evaluated for all treated participants using National Cancer Institute Common Terminology Criteria for Adverse Events v4.0 (NCI CTCAE v.4.0).
Number of Participants With Best Overall Response
时间窗: Day 1, at each returning on-treatment visit and the first post-treatment visit
Participants were clinically assessed for IWG-(International Working Group consensus criteria for treatment response in myelofibrosis with myeloid metaplasia) defined response at each returning on-treatment visit and the first post-treatment visit. IWG-MRT criteria for best overall response are ordered high to low: CR\>PR\>CI\>SD\>PD\>R where CR = Complete Remission, PR= Partial Remission, CI = Clinical Improvement, SD = Stable Disease, PD = Progressive Disease and R = Relapse. Best overall response is the best response of the subject during the treatment period or at the first post-treatment visit.
次要结局
- Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinite Time (for Single Dose Period Only) (AUC(INF)) of BMS-911543 and it's Metabolite Met4(Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study)
- Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Plasma Concentration (for Single Dose Period Only) (AUC(0-T)) of BMS-911543 and it's Metabolite Met4(Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study)
- Changes in (Janus Kinase) JAK/Signal Transducers and Activators of Transcription (STATs) Pathway Activities, Circulating CD34+ Cells and Plasma Cytokine Levels(Up to 6 months)
- Trough Observed (Pre-dose) Plasma Concentration (Cmin) of BMS-911543 and it's Metabolite Met4(Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study)
- Maximum Observed Plasma Concentration (Cmax) of BMS-911543 and it's Metabolite BMS-926796 (Met4)(Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study)
- Time of Maximum Observed Plasma Concentration (Tmax) of BMS-911543 and it's Metabolite Met4(Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study)
- Area Under the Concentration-time Curve in One Dosing Interval (AUC(TAU)) of BMS-911543 and it's Metabolite Met4(Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study)
- The Terminal-phase Elimination Half-life in Plasma (T-HALF) of BMS-911543 and it's Metabolite Met4(Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study)
- Apparent Total Clearance (for Parent Compound Only) (CLT/F) of BMS-911543 and it's Metabolite Met4(Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study)
- Apparent Volume of Distribution After First Dosing Based on the Terminal Phase (for Parent Compound Only) (Vz/F) of BMS-911543 and it's Metabolite Met4(Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study)
- Accumulation Index (AI): Ratio of AUC(TAU) on Day 15 to AUC(TAU) After the First Dose of BMS-911543 and it's Metabolite Met4(Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study)
- Ratio of BMS-926796 AUC(INF) to BMS-911543 AUC(INF) After 1st Dose and BMS-926796 AUC(TAU) to BMS-911543 AUC(TAU) on Day 15 (AUC Ratio)(Day -1, Day 1, Day 8, Day 15, Day 21 and Day 28 or off-study)